menu trigger  menu trigger
OutpatientsMon - Fri 08:00-17:00(+357) 25 208 000[email protected]1, Nikis Avenue, Agios Athanasios4108 Limassol, Cyprus
Website Development by ISTODATA
Medical Oncologist

GEORGE ORPHANOS

Contact Us

ADMINISTRATION

Athina Georgiou
(+357) 25 208 189
[email protected]
Dr. George Orphanos comes from the village of Akanthou, in the occupied by the Turkish army part of northern Cyprus. He completed his high school studies at the Lanitio High School in Limassol and then studied at the Medical School of the University of Athens. He majored in Pathological Oncology and worked at the Agios Savvas and Laiko hospitals in Athens and at Saint Bartholomew’s in London. Returning to his homeland, he worked as a specialist oncologist at the General Hospital of Nicosia, at the Bank of Cyprus Oncology Center in Nicosia, and in private clinics in Limassol and Paphos. The proposal-challenge from the German Oncology Center found him ready and willing for the next step, and so, in April 2020 he joined the Team.

Oncology is the branch of medicine that gives you the opportunity to touch not only the patient’s organic problem, but also his or her psyche, the person as a whole. Despite the practical difficulties of practicing oncology, ie administering complex treatments with a serious degree of toxicity and side effects, the oncologist has to give courage and hope to the patient, taking away his or her stress and agony, opening-up a new perspective for his/her life, and treating the medical problem. This constant battle requires huge mental reserves from the doctor / therapist, who must somehow find ways to replenish them, otherwise he will inevitably distance himself from the patient, and the mental bond he must have with him/her may crack and break. The relationship between the two is reciprocal and should be based on mutual trust, honesty, and undiminished interest.

Oncology is the fastest growing medical specialty, with scientific knowledge being enriched daily. Thus, the oncologist is called to be constantly informed and up-to-date with all important developments.
The effort to combine scientific knowledge with the caring and offering the best to your patients, is part of our everyday life here at the German Oncology Center, as a member of which I was invited to join the Journey and, by participating in its Interdisciplinary Team, I try with all my colleagues to provide the best possible support to each and every one of our patients.

George Orphanos
More about Dr. George Orphanos

CURRICULUM VITAE

  • Education
  • Professional Career
  • Publications
  • Presentations at International Conferences
  • 1990-1996: Degree in Medicine, University of Athens, Greece
  • 2006: Acquired his medical specialty degree in Pathology-Oncology
  • 1996-1997: Trainee doctor, Limassol General Hospital
  • 1998-2000: Specialty in Pathology, at the 2nd Pathology Clinic of Agios Savvas Cancer Hospital of Athens
  • 2000-2001: Specialization in Hematology (within the specialty of Pathological Oncology), Athens “Laiko Hospital”
  • 2001-2002: Assistant physician, at the Bank of Cyprus Oncology Center
  • 2003-2006: Specialty in Pathological Oncology, at the 1st Pathological Clinic, Agios Savvas Cancer Hospital of Athens
  • 2004: Specialty in Pathological Oncology, Saint Bartholomew’s Hospital London
  • 2006-2008: Medical Officer, Oncology Clinic, Nicosia General Hospital Nicosia
  • 2008-2014: Private Pathologist – Oncologist. Associate of the Hygeia Polyclinic, Limassol, and at Evangelismos Hospital, Paphos
  • 2014-2018: Pathologist-Oncologist, Bank of Cyprus Oncology Center, Nicosia, Cyprus.
  • 2018-2020: Private Pathologist-Oncologist. Associate of Hygeia Polyclinic, Limassol, Cyprus
  • April 2020 – Today: Medical Oncologist at The German Oncology Center, Limassol, Cyprus
  1. Orphanos G, Ioannidis G, Ioannou R, Zouvani I.  Alveolar soft part sarcoma with breast metastases: A case report. Med Oncol. 2013 Mar;30(1):342.
  2. Orphanos G, Kountourakis P.Targeting the HER2 Receptor in Metastatic Breast Cancer. Hematol Oncol Stem Cell Ther. 2012;5(3):127-37.
  3. Saha   A, Varughese  M,  Gallagher C.J, Orphanos G,  Wilson P, Oram D, Jeyarajah A, Reynolds K,    Shepherd J ,  McCormack  M,  OlaitanA, McDonald N, Mould T,  McNeish I, Ledermann J.A.  Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. Int J Gynecol Cancer. 2012 May;22(4):566-72.
  4. Orphanos G, Charalambous C,  Vrezas I, Kales SN, Haralambous H, Katodritis N, Christodoulides G,   Maimaris M,  Soteriades ES. Mesothelioma in Cyprus: A case series  (1997 – 2007). Hematol Oncol Stem Cell Ther. 2011;4(4):193-194.
  5. Orphanos G, Stavrou NG, Picolos MK. Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy.  Acta Oncol. 2010;49(2):262-3.
  6. Orphanos G, Ardavanis A.  Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. Clin Exp Metastasis. 2010;27(1):19-23.
  7. Orphanos G, Ioannidis GN, Ardavanis A.  Cardiotoxicity induced by tyrosine kinase inhibitors.Acta Oncol. 2009;48(7):964-70.
  8. Orphanos G, Alexopoulos A, Malliou S, Ioannidis G, Ardavanis A, Kandylis C, Stavrakakis J, Rigatos G.   A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Cancer Res Clin Oncol. 2010 Jan;136(1):115-21.
  9. Orphanos G, Ardavanis A, Charalambous P, Stavrakakis J, Rigatos G.  Systemic sclerosis associated with rectal cancer. Case report and a brief review of the literature. In Vivo. 2008 Nov-Dec;22(6):825-9.
  10. Orphanos G, Kakoullou N, Ardavanis A.  Is overcoming hormone resistance in breast cancer possible? J BUON.2008 ;13(3): 315-22.
  11. Orphanos G, Ioannidis G, Michael M, Kitrou G.  Prostate-specific antigen in the cerebrospinal fluid: A marker of local disease.  Med Oncol. 2009;26(2):143-6.
  12. Ardavanis A, Orphanos G, Skafida S, Basioukas S, Rigatos G.  Coincidental successful treatment of Jessner-Kanof disease with chemotherapy.  Ann Oncol. 2008 Jul;19(7):1360-1.
  13. Ardavanis A, Kountourakis P, Orphanos G, Rigatos G.  Low-dose capecitabine in breast cancer patients with symptomatic bone marrow infiltration: a case study. Anticancer Res. 2008 Jan-Feb;28(1B):539-41.
  14. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, Salagianni ML, Orphanos G, Baxevanis CN ,Rigatos G, Papamichail M.  CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients. Clin Cancer Res.2007 May 1;13(9):2714-21.
  15. Ardavanis A, Orphanos G, Ioannidis G, Rigatos G.  Skin metastases from primary lung cancer. Report of three cases and a brief review.  In Vivo. 2006 Sep-Oct; 20(5):671-3.
  16. Arrdavanis A, Scorilas A, Tryfonopoulos D, Orphanos G, Missitzis I, Karamouzis M, Chrysochoou M, Sotiropoulou A, Arnogiannaki N, Ioannidis G, Pissakas G, Rigatos G.  Multidisciplinary therapy of locally far advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and fluorouracil chemotherapy, surgery, and radiotherapy: longterm results. Oncologist. 2006 Jun;11(6):563-73
  17. Ardavanis AS, Ioannidis GN, Orphanos GS, Rigatos GA.  Salvage treatment with  single agent Capecitabine in patients with heavily pretreated advanced colorectal cancer. Anticancer Research.2006; 1669-1672.
  18. Ardavanis A., Tryfonopoulos D., Orphanos G., Ioannidis G., Karamouzis M., Rigatos G. First line chemotherapy with Fluorouracil-Epirubicin-Navelbine (FEN) combination in advanced breast cancer. Anticancer Research. 2005; 25: 4493 – 4498.
  19. Ardavanis A., Tryfonopoulos D., Orfanos G., Karamouzis M., Scorilas A., Alexopoulos A., Rigatos G.  Safety and efficacy of Trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER-2 positive recurrent breast cancer: findings from case series. Onkologie. 2005; 28:558 – 564.
  20. Vassilomanolakis M., Koumakis G., Barbounis V., Orphanos G., Efremidis A.  Prevention of vinorelbine phlebitis with cimetidine. Supportive care in cancer. 2001; 9.2:108 – 111.

Publications in Greek medical journals

  1. Vomvas D., Orphanos G.,Kyriakou F., Charalambous H., Katodrotis N. The role of radiotherapy in lung cancer. Cyprus Medical Review 2017;2(3):13-22.
  2. Ardavanis A.,Orphanos G. Is overcoming hormone resistance in breast cancer possible? Forum of Clinical Oncology 2006;5(3):243-250.
  3. Orphanos G., Ardavanis A., Charalambous P., Rigatos G. Systemic sclerosis in a patient with rectal adenocarcinoma. A rare case report and review of the literature. Hellenic rheumatology 2005;16(3):244-248.
  4. Bagkatzounis Th., Stavrou N., Allayiotou M., Orphanos G., Panayiotou S. Malignant hemangiopericytoma of the pelvis. Hellenic Surgical Oncology 2004; 4.2:101 – 104.
  5. Karamouzis M., Orphanos G., Lainakis G., Papadopoulou A., Skorilas A., Rigatos G. Evaluation of social support in a random cohort of patients with malignant tumors. Hellenic Oncology. 2003; 39.4:239 – 244.
  6. Vassilomanolakis M., Koumakis G., Orphanos G., Kanakakis V., Koilakou S., Skafida S., Kambletsas E., Demiris M., Efremidis A. Characteristics and frequency of symptomatic (chemical) phlebitis after i.v. injection of Vinorelbine. Hellenic Oncology. 2000; 36.1:45 – 48.

European Society for Medical Oncology-ESMO 2018
P. Kountourakis, A. Agathocleous, E. Kakouri, Y. Marcou, G. Orphanos, F. Kyriacou, D. Papamichael.
Poster: Hepatitis screening for patients to undergo chemotherapy in Cyprus. Ann Oncol (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

8th International Oncology Week of the World Federation of Surgical Oncology Societies, 2017
G. Orphanos.
Oral presentation: Modern principles of Immunotherapy of Cancer

The 3rd Cyprus Oncology Conference: New frontiers in Cancer Prevention and Personalized Treatment, 2017
G. Orphanos
Oral presentation: Management of toxicity of immunotherapy

American Society of Clinical Oncology – ASCO, 2006
G. Orphanos, A. Alexopoulos, G. Ioannidis, C. Kandylis, A. Ardavanis, J. Stavrakakis, G. Rigatos.
Publication: High efficacy and low toxicity of the combination of Vinorelbine and Capecitabine as second line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. J Clin Oncology.2006;24.18S (abstract No 10719)

American Society of Clinical Oncology – ASCO, 2005
C.J. Gallagher, G. Orphanos, M. Perianan, A. Saha, P. Wilson, R. Reznek, D. Oram A. Jeyarajah, K. Reynolds, J. Shepherd.
Poster: Treatment of women with abdominal carcinomatosis of suspected ovarian origin and prognostic importance of response to primary chemotherapy. J Clin Oncology. 2005; 23.16S: 471 (abstract No 5069)

European Society for Medical Oncology Scientific & Educational Conference ESEC, Budapest 2005
G.Ioannidis, A.Ardavanis, G.Orphanos, G.Rigatos
Poster: Salvage treatment with single agent Capecitabine in patients with heavily pretreated advanced colorectal cancer. Ann Oncology. 2005;16.S2: ii286 (abstract No 58P)

6th Central European Lung Cancer Conference, Budapest 1999
G.Koumakis, V.Barbounis, M.Vassilomanolakis, H.Hatzichristou, M.Demiri, E.Psaras, V.Kanakakis, G.Orphanos, A.Efremidis.
Phase I-II trial of weekly Paclitaxel in advanced non-small cell lung cancer (N.S.C.L.C.): a preliminary report.

© German Oncology Center. All rights reserved.

Website Development by ISTODATA